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Abstract
Persistent activation of STAT3 plays amajor role in cancer progression and immune escape. Therefore, targeting STAT3
in tumors is essential to enhance/reactivate antitumor immune response. In our previous studies, we demonstrated the
efficacy of stearic acid–modified polyethylenimine (PEI-StA) in promoting small interfering RNA (siRNA) silencing of
STAT3 in B16.F10 melanoma in vitro and in vivo. In the current study, we examine the immunologic impact of this
intervention. Toward this goal, the infiltration and activation of lymphocytes and dendritic cells (DCs) in the tumor
mass were assessed using flow cytometry. Moreover, the levels of IFN-γ, IL-12, and TNF-α in homogenized tumor
supernatants were determined. Moreover, mixed lymphocytes reaction using splenocytes of tumor-bearing mice
was used to assess DC functionality on siRNA/lipopolyplexes intervention. Our results demonstrated up to an ap-
proximately fivefold induction in the infiltration of CD3+ cells in tumor mass on STAT3 knockdown with high levels
of CD4+, CD8+, and NKT cells. Consistently, DC infiltration in tumor milieu increased up to approximately fourfold.
Those DCs were activated, in an otherwise suppressive microenvironment, as evidenced by a high expression of
costimulatory molecules CD86 and CD40. ELISA analysis revealed a significant increase in IFN-γ, IL-12, and TNF-α.
Moreover, mixed lymphocytes reaction demonstrated alloreactivity of these DCs as assessed by high T-cell prolifera-
tion and IL-2 production. Our results suggest a bystander immune response after local STAT3 silencing by siRNA. This
strategy could be beneficial as an adjuvant therapy along with current cancer vaccine formulations.
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Introduction
Immune evasion is a hallmark of cancer progression and develop-
ment [1,2]. To evade immune detection and eradication, tumors pos-
sess a major strategy through persistent activation of signal transducer
and activator of transcription 3 (STAT3) [3–6]. This downstream
protein is a transcription factor that becomes activated in response
to cytokines and growth factor receptor stimulation. On stimulation,
STAT3 monomers get phosphorylated and then form homodimers
or heterodimers that translocate to the nucleus to upregulate the ex-
pression of target genes. In a variety of tumor cells, activated STAT3
promotes transcription of genes responsible for cell survival and pro-
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liferation, angiogenesis, metastasis, as well as immune escape [7,8].
For immune escape property, STAT3 impact appears at two levels:
the cell-intrinsic level and the cell-extrinsic level. The cell-intrinsic
mechanisms encompass changes in cancer cells that have resulted
from persistently active STAT3. For instance, constitutively active
STAT3 suppresses the production of the chemokines RANTES
and IP-10 that are responsible for T-cell recruitment [3]. Another
example is the down-regulation of the tumor cell surface expression
of Fas receptor (CD95), which is a proapoptotic receptor involved in
cytotoxic T lymphocyte (CTL)–dependent cytotoxicity [9]. Con-
versely, the cell-extrinsic level is orchestrated by the ability of STAT3
to mediate a cross-talk between cancer and immune cells [10–12]. In
this scenario, tumor-derived factors (TDFs) produced by STAT3-
active tumors induce the activation of STAT3 in multiple subsets of
innate and adaptive immune cells [11,13]. On STAT3 hyperactivity,
innate immune cells such as natural killer (NK) cells, tumor-associated
macrophages, NKT cells, and neutrophils lose their ability of tumor
inhibition or effective production of immunostimulatory molecules
[11]. One of the most important affected cell subsets in this equation
is dendritic cells (DCs), as they form the link between the innate and
adaptive arms of the immune response owing to their ability as the
most potent antigen-presenting cells. The immunosuppressive milieu
induces the production of immunosuppressive TDFs that further in-
hibit DC maturation and results in the inhibition of TH1-type im-
mune response and CTL cytotoxicity [3]. Thus, in the presence of
cancer, DC malfunction causes an immunologic paralysis leading to
the potentiation of cancer progression [5,14]. Therefore, breaking this
cycle of tolerance by targeting persistently active STAT3 in tumors is
essential to reactivate the immune system for a robust antitumor re-
sponse in an otherwise immunosuppressive microenvironment.
RNA interference mediated by small interfering RNA (siRNA) pro-
vides a very specific and effective modality to downregulate protein
expression at the mRNA level [15]. Despite great potential, siRNA tech-
nology suffers from fundamental drawbacks such as low biologic stability,
poor cell permeability, and unfavorable pharmacokinetic and biodistribu-
tion profile that hinder its progress from bench to bedside [16]. There-
fore, it is essential to develop a delivery system that optimally delivers
siRNA to its site of action while retaining its silencing activity [17].
We have recently developed a polymeric systems for siRNA delivery
to B16 melanoma cells based on stearic acid (StA) substitution on poly-
ethylenimine (PEI) backbone, where such modification led to better
siRNA stability in biologic milieu, effective down-regulation of STAT3
at low siRNA doses, resulting in the inhibition of B16 cell growth both
in vitro and in vivo [18]. Moreover, a reduction in the level of vascular
endothelial growth factor (VEGF), an increase in interleukin-6 (IL-6)
production, and a rise in caspase 3 activity in isolated tumor mass on
siRNA intervention was noted [18]. In the present study, the effect of
STAT3 down-regulation by its siRNA/stearic acid–modified poly-
ethylenimine (PEI-StA) complexes in tumor cells on the trafficking
and activity of tumor-derived immune cells including DCs has been in-
vestigated to assess whether effective knockdown of STAT3 in the effec-
tor phase can break the vicious cycle of immunosuppression in tumor
microenvironment and lead to better antitumor immune responses.
Materials and Methods
Animals
All animal studies were conducted in accordance with the Canadian
Council on Animal Care Guidelines and Policies with approval from
the Animal Care and Use Committee: (Biosciences, Health Sciences
or Livestock) for the University of Alberta. All experiments were per-
formed using 4- to 6-week-old male mice. Male BALB/c and C57BL/
6 mice were purchased from Jackson Laboratory (Bar Harbor, ME).
Materials
Branched PEI (25 kDa), triethylamine (TEA), 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide,
and stearoyl chloride (98.5%) were obtained from Sigma-Aldrich (St
Louis, MO). Anhydrous ethyl ether and dichloromethane were pur-
chased from Fisher Scientific (Fairlawn, NJ). Fetal bovine serum (FBS)
was obtained from HyClone (Logan, UT). Dulbecco modified Eagle,
RPMI-1640, L-glutamine, and gentamicin were purchased from Gibco-
BRL (Burlington, Ontario, Canada). Mouse interleukin 2 (IL-2), IL-12,
tumor necrosis factor α (TNF-α), and interferon-γ (IFN-γ) ELISA kit
was purchased from e-Biosciences (San Diego, CA). Sequence-specific
siRNA targeting murine STAT3 mRNA was purchased from Ambion
(Austin, TX) (sense: 5′-GGACGACUUUGAUUUCAACtt-3′, anti-
sense: 5′-GUUGAAAUCAAAGUCGUCCtg-3′). The nontargeting
(NT) siRNA Silencer Negative Control no. 1 siRNA (catalog no.
AM4635) and Silencer FAM-labeled Negative Control no. 1 siRNA
(catalog no. AM4620), both purchased from Applied Biosystems
(Foster City, CA). Caspase 3 assay kit, Nonidet P-40, protease inhibitor
cocktails, and 4-nitrophenyl phosphate were purchased from Sigma-
Aldrich. Antiphosphotyrosine (Y705) STAT3 monoclonal antibody,
anti-STAT3 antibody, and antiactin antibody (I-19) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). ECL Plus Detection
Kit was purchased from GE Healthcare Life Sciences (Piscataway, NJ).
Antimouse CD3 (FITC-labeled), CD4 (phycoerythrin [PE]-Cy5–
labeled), CD8 (PE-Cy5–labeled), NK1.1 (PE-labeled), CD11c (FITC-
labeled), CD86 (PE-labeled), and CD40 (PE-Cy5–labeled) mAbs, or
corresponding isotype controls, were purchased from BD Biosciences
(Mississauga, Ontario, Canada). EasySep Negative Selection Kit for
T-cell isolation was purchased from StemCell Technologies (Vancouver,
British Columbia, Canada).
Preparation of siRNA Complexes
PEI-StA was prepared by N -acylation of PEI with stearoyl chloride
and characterized as described in Alshamsan et al. [19]. Then, in sterile
Eppendorf tubes, equal amounts (μg) of siRNA and PEI or PEI-StA in
PBS were incubated for 30 minutes at 37°C as previously described
[18]. Samples were freshly prepared before each administration.
Assessing the Effect of Medium from Untreated and
siRNA-Treated B16 Cells on In Vitro DC Maturation
and Function
B16.F10 treatment. For STAT3 targeting, 1 × 105 B16 melanoma
cells were incubated (in 24-well plates) for 36 hours at 37°C with
titrated doses of anti-STAT3 siRNA (6.25-400 nM) delivered by
PEI or PEI-StA complexes. Identical complexes of NT siRNA as well
as untreated B16 cells were used as controls. To remove the uninter-
nalized complexes, B16 medium was replenished after 8 hours of in-
cubation. Then, cells were lysed, and levels of active phosphorylated
STAT3 (p-STAT3) as well as total STAT3 were detected by Western
blot (see below). The optical intensity of p-STAT3 band was quan-
tified and normalized to actin protein band using ImageJ software
(W. Rasband [2005], National Institutes of Health, Bethesda, MD;
http://rsb.info.nih.gov/ij). The percentage of p-STAT3 silencing was
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calculated at each dose by comparing the level of STAT3 in the test
group versus the level of STAT3 in the untreated cells (considered as
100%). Simultaneously, on 96-well plate, cancer cell viability was de-
termined by MTTassay and caspase 3 activity assay after the 36 hours
of incubation with siRNA complexes; in these assays, a single con-
centration of siRNA was used (50 nM).
DC treatment. Primary DC culture was generated from bone mar-
row precursor of C57BL/6 mice femurs and propagated in complete
RPMI-1640 in the presence of GM-CSF as previously described [20].
The purity of the DC population on day 7 was found to be between
70% and 75% based on the expression of CD11c on the semiadherent
and nonadherent cell populations. To increase DC purity, semiadher-
ent and nonadherent cells were isolated from primary culture on day 6
by thorough suspension in growth medium. Cells were centrifuged
and resuspended in fresh complete RPMI-1640 in the presence of
granulocyte-macrophage colony-stimulating factor and then trans-
ferred to new cell culture plates 24 hours before any manipulation.
After this process, 95% of cells were confirmed to be positive for
CD11c. Malfunctioned DCs at day 7 were generated by exposure
to tumor-conditioned medium from B16.F10 melanoma culture
(B16-CM) for 24 hours as previously described in Alshamsan et al.
[21]. In brief, murine B16.F10 cells were grown and propagated in
Dulbecco modified Eagle medium supplemented with 10% FBS
at 37°C and 5% CO2. After confluence, B16 cells were incubated
with serum-free medium for 24 hours. This medium was collected
and grouped according to the designated treatment into anti-STAT3
siRNA complexes treated (B16-CM/PEI and B16-CM/PEI-StA),
NT siRNA complexes treated (B16-CM/PEI[NT] and B16-CM/
PEI-StA[NT]), and untreated B16-CM. Thereafter, the conditioned
medium from each treatment group was added to a primary DC cul-
ture, reaching a final B16-CM concentration of 50%. FBS was then
supplemented to 10% final concentration in culture. After that, DC
phenotypic maturation was evaluated by surface expression of CD40
and CD86 as analyzed by flow cytometry (FCM). Moreover, mixed
lymphocytes reaction (MLR) was performed as described below to as-
sess DC function as indicated by their capability to stimulate allogenic
T-cell proliferation.
Western blot. Cells were collected and washed twice with ice-cold
PBS. Then, sample tubes were imbedded in ice, and cells were lysed
in lysis buffer containing 30 mM HEPES (pH 7.5), 2 mM Na3VO4,
25 mM NaF, 2 mM EGTA, 2% Nonidet P40, 1:100 protease inhib-
itor cocktails, 0.5 mM dithiothreitol, and 6.4 mg/ml phosphatase
substrate 4-nitrophenyl phosphate. Cell lysates were centrifuged
for 20 seconds at 16,000g. Thereafter, NaCl was added to samples
to final concentration of 420 mM, cell lysates were centrifuged for
20 minutes at 16,000g, the supernatant was transferred to new tubes,
and pellets were discarded. Total protein extract was determined by
Micro BCA Protein Assay Kit. Equal amounts of protein (20 μg)
were mixed with equal volumes of loading buffer (0.5 M Tris-HCl
pH 6.8, 20% glycerol, 10% SDS, 1.5% bromophenol blue, 5%
β-mercaptoethanol). Samples were dipped in boiling water for 5 min-
utes then loaded on 8% SDS-PAGE gel. Electrophoresis was con-
ducted in running buffer (25 mM Tris base, 192 mM glycine,
0.1% SDS). For the first 30 minutes, the run was conducted under
60 V then it was increased to 120 V for 90 minutes. Proteins were
then transferred into activated polyvinylidene fluoride membrane in
transfer buffer (1 L contains: 200 ml of methanol, 2.4 g of Tris base,
14.2 g of glycine, 0.1 g of SDS) at 140 V for 2 hours. Thereafter, the
membrane was incubated overnight at 4°C with blocking buffer con-
taining 5% skimmed milk and 0.5% bovine serum albumin (BSA) in
Tris-buffered saline containing 0.1% (vol/vol) Tween-20 (TBS-T).
Then, membranes were thoroughly washed in TBS-Tand then probed
with antiphosphotyrosine (Y705) STAT3 monoclonal antibody at a
1:500 dilution for 2 hours. The membrane was then washed five times
(5 minutes per wash) with TBS-T under gentle shaking. Then, goat
antimouse polyclonal Ab at 1:50,000 was added to the membranes
in blocking buffer and kept at room temperature for 90 minutes under
gentle shaking. The membrane was then washed five times (5 minutes
per wash) with TBS-Tunder gentle shaking and developed using ECL
Plus Detection Kit. The membranes were incubated with stripping
solution (100 mM β-mercaptoethanol in TBS-T) at 37°C for 30 min-
utes. They were then washed, blocked, and probed with anti-STAT3
Ab and antiactin Ab (I-19) at 1:1000 dilution. Membranes were de-
veloped using ECL Plus Detection Kit.
MTTassay. B16 cells, grown in 96-well flat-bottomed microplates,
were treated as indicated. Thereafter, 100 μl of MTT solution in cul-
ture medium (0.5 mg/ml) was added to each well for 2 hours. The
formed formazan crystals were dissolved by adding 200 μl of dimethyl
sulfoxide to each well. Optical density was measured at 550 nm using
a microplate reader (Powerwave with KC Junior software; Bio-Tek,
Winooski, VT). The results were converted into percentage viability
relative to the untreated sample.
Caspase 3 activity assay. The caspase 3 activity was measured as
an indicator for apoptosis. For that purpose, B16 cells were treated
with 50 nM siRNA in PEI or PEI-StA for 24 hours. Using caspase 3
assay kit, cells were normalized for 105 cells per treatment group,
lysed, and placed in designated wells in 96-well flat-bottomed micro-
plates. Provided caspase 3 inhibitor (Ac-DEVD-CHO) and caspase 3
substrate (Ac-DEVD-pNA) were then added to designated wells ac-
cording to the manufacturer’s instructions. Optical density was mea-
sured at 405 nm using microplate reader, and caspase 3 activity was
calculated based on p-nitroaniline calibration curve.
Flow cytometry analysis. For phenotypicmaturation studies, 1 × 105
DC primary cultures were washed with PBS and suspended in FCM
buffer (PBS with 5% FBS). Then, cells were incubated with CD86
and CD40 mAbs or corresponding isotype controls and kept in 4°C
for 30 minutes. After that, cells were washed three times with FCM
buffer to remove excess mAbs, and all samples were finally acquired
on a Becton-Dickinson FACS and analyzed by Cell-Quest software
(BD Biosciences, Franklin Lakes, NJ).
Mixed lymphocyte reaction. T cells were obtained from spleen of
BALB/c mice Jackson Laboratory. Spleen was crushed between two
slides, and T cells were purified using EasySep Negative Selection kit
according to the manufacturer’s instructions. Purified T cells were
cocultured in flat-bottomed 96-well plates with irradiated DCs at a
ratio of 2:1 in 37°C and 5% CO2. Thereafter, [
3H]-thymidine was
added during the last 18 hours of a 3-day coculture, and the T-cell
proliferation was measured by [3H]-thymidine incorporation in counts
per minute. The corresponding secretion of IL-2 was determined by
ELISA in a 96-well microplate using a microplate reader (Powerwave
with KC Junior software; Bio-Tek) at an optical density of 450 nm with
reference set at 570 nm. All samples were analyzed in at lease triplicates.
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Assessing the Effect of Anti-STAT3 siRNA Complex Treatment
of B16 Tumors on Immune Response In Vivo
Tumor establishment and treatment. B16 tumor was established
as described earlier in Alshamsan et al. [18]. In brief, 0.75 × 106 B16
cells were inoculated subcutaneously in the upper left flank of male
C57BL/6 mice. After 10 days, 500 pmol of STAT3-targeting siRNA
complexes (PEI and PEI-StA) or NT siRNA complexes (PEI[NT] and
PEI-StA[NT]) in normal saline were administered to randomly as-
signed groups (five to seven mice per group) by intratumoral (i.t.)
injections on daily basis for 4 days. siRNA complexes were freshly pre-
pared before each administration as described previously in Alshamsan
et al. [18]. Additional control group received daily i.t. injections of
normal saline without any formulation.
Assessing tumor growth and STAT3 expression. Tumor dimen-
sions were measured by vernier caliper after 1 day of the final treat-
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Thereafter, mice were killed; tumor samples were immediately iso-
lated and crushed between two slides to form uniform cell suspension
and analyzed for STAT3 expression by Western blot as described in
the in vitro study.
Evaluating the immunologic profile in tumor milieu. Superna-
tants of each tumor sample were analyzed for protein content by Micro
BCA Protein Assay, normalized, and analyzed for IL-12, TNF-α, and
IFN-γ using corresponding ELISA kit as mentioned earlier. Further-
more, immune cells were evaluated for cell percentage and activa-
tion level by FCM as previously mentioned. For that purpose, each
cell suspension was incubated with antimouse CD3, CD4, CD8,
NK1.1, CD11c, CD86, and CD40 mAbs or corresponding isotype
controls and kept in 4°C for 30 minutes. Then, cells were washed
three times with FCM buffer to remove excess mAbs, and 1 × 106 cells
were finally acquired from each sample on a Becton-Dickinson
FACS and analyzed by Cell-Quest software.
Evaluation of DC functionality after siRNA treatment in vivo. To
assess DC functionality in tumor-bearing mice after STAT3 knock-
down, MLR was conducted. Splenocytes from each treatment group
were isolated, irradiated, and cocultured with purified T cells from
BALB/c mice in 37°C and 5% CO2. T-cell proliferation was measured
as described earlier. Similarly, IL-2 level in each sample was measured
by ELISA as described earlier.
Data Analysis
Data were analyzed for statistical significance (P < .05) by one-way
analysis of variance; post hoc Scheffé test was conducted to determine level
of significance (Version 16.0; SPSS for Windows; IBM, Chicago, IL).
Results
STAT3 Knockdown in B16 by siRNA Induces DC Maturation
and Activation In Vitro
We have previously shown that, on exposure to B16-CM, DCs re-
main in the inactive state [21]. The results of this study demonstrated
that the immunosuppressive effect of B16-CM on DCs could be re-
versed by silencing STAT3 in B16 cells before DC exposure. Targeting
B16 cells with anti-STAT3 siRNA in PEI and PEI-StA complexes
caused knockdown of STAT3 expression in a specific and dose-
dependent fashion (Figure 1, A and B). However, PEI-StA complexes
showed superior inhibitory effect on the level of p-STAT3 expression
(compared with PEI) as evidenced by the increase in p-STAT3 silenc-
ing percentage at most concentrations tested (Figure 1A). When B16
cells were treated with an siRNA concentration of 50 nm, complexes
formed by PEI-StA have induced a significant knockdown of the level
of both p-STAT3 and STAT3 compared with PEI-treated group
(Figure 1B). This corresponded to a cytotoxic effect on B16 cancer
cells as shown by up to 30% reduction in cell viability (Figure 1C ,
top panel ) and more than twofolds induction in the activity of the
apoptotic protein caspase 3 (Figure 1C , bottom panel ). The exposure
of DCs to B16-CM from B16 cells in which STAT3 was silenced by
PEI or PEI-StA/siRNA complexes induced phenotypic DC maturation
indicated by the significantly higher surface expression of CD86 and
CD40 compared with controls. For both markers, the surface expres-
sion was higher by B16-CM/PEI-StA treatment where it allowed
for an induction reaching 89% for CD86 (Figure 2A) and 66% for
CD40 (Figure 2B) higher than that of B16-CM/PEI treatment. Bar
graphs show mean fluorescence intensity (MFI) values after each treat-
ment where B16-CM/PEI-StA treatment gives more MFI signals than
treatments with controls (*P < .05) and B16-CM/PEI (aP < .05) for
both CD86 and CD40. Consistently, DCs activity, characterized by
their ability in recognition and priming of allogenic T cells, was also
restored after STAT3 silencing in B16 cells (Figure 2C). T cells co-
cultured with DCs from B16-CM/PEI or B16-CM/PEI-StA groups
showed a significant increase in their proliferation compared with con-
trols (P < .05). Similar to the phenotypic DC maturation results, DCs
showed enhanced functionality when exposed to B16-CM/PEI-StA
compared with B16-CM/PEI (P < .05; Figure 2C , left panel ). It is
worth noting that IL-2 that is concomitantly secreted from T cells
during their proliferation followed a similar pattern where its maxi-
mum level was detected after T-cell coculture with DCs from B16-
CM/PEI-StA group (Figure 2C , right panel ). This is consistent with
our FCM results because DCs exposed to B16-CM/PEI-StA showed
a significantly higher expression of costimulatory molecules compared
with that of B16-CM/PEI (data from Figure 2, A and B).
Tumor Growth Inhibition after STAT3 Knockdown In Vivo
Tumor growth study after STAT3 knockdown in B16 tumors by
siRNA revealed significant tumor regression of the treated tumor
masses compared with controls as a result of STAT3 knockdown
(Figure 3A). PEI-StA complexes significantly reduced tumor growth
compared with saline-treated control (P < .05) and PEI-treated group
(P < .05). In fact, tumor volume analysis confirmed uniformity of
treatment and response as indicated by close adherence of subjects
in each group to the group average (Figure 3A, top panel ). Average
tumor volume dramatically dropped from ∼390 mm3 in the untreated
group to ∼170 mm3 in case of PEI complexes. It is worth noting that
further reduction in tumor volume was noticed with PEI-StA com-
plexes where it reached ∼42 mm3 after 24 hours of the final treatment
dose. Similarly, STAT3 expression in vivo, measured in isolated tu-
mors 1 day after the final treatment dose, was significantly reduced
on siRNA administration by PEI and PEI-StA complexes reaching
25% and 55% less than that of saline-treated control, respectively
(Figure 3A, bottom panel ). Figure 3B shows the representative three
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mice per treatment group at the end point of the study (after 24 hours
of final treatment). Our current results are consistent with our previ-
ous findings where the stearic acid derivative of PEI increased both
stability and potency of siRNA in vitro and in vivo [18,19]. The results
also indicate a uniformity in response to treatment, where each single
subject who received the anti-STAT3 siRNA PEI or PEI-StA com-
plexes showed a reduction in tumor mass compared with NT or un-
treated controls. Besides, the antitumor effect was better in each single
subject of the PEI-StA group compared with PEI group, indicating the
potency provided by the lipid-modified formulation.
Induction of DC Activation In Vivo after STAT3 Knockdown
in B16 Tumor
To evaluate DC infiltration and activation, FCM analysis was per-
formed for the DC lineage marker CD11c and activation markers
CD86 and CD40 in tumor cell suspensions after designated treat-
ments of B16 tumors. Our results demonstrate up to an approxi-
mately fourfold increase in CD11c+ DC infiltration in B16 tumor
mass on STAT3 knockdown (Figure 4A, top panel ). However, no
statistically significant difference was noted between PEI and PEI-
StA treatment groups. In PEI and PEI-StA groups, further analysis
of DC population showed an increase in the surface expression of
both CD86 and CD40, reaching up to 35% and 48% higher than
NT siRNA and saline control treatments (Figure 4A, bottom panel ).
PEI-StA complexes of STAT3 siRNA also allowed for an increase in
CD86 and CD40 expression that was 16% higher than that of PEI
complexes. Moreover, ELISA analysis of tumor supernatants indi-
cated the production of high levels of proinflammatory cytokines
IL-12 and TNF-α after STAT3 knockdown (Figure 4B). The results
clearly show that PEI-StA complexes allowed for a significant increase
in TNF-α and IL-12 production that was 38% and 129% higher
than what was measured with PEI complexes, respectively.
Figure 1. B16.F10 cell death after STAT3 knockdown by anti-STAT3 siRNA complexes in vitro. (A) Confluent B16 cells were incubated for
36 hours with titrated doses of anti-STAT3 siRNA (6.25-400 nM) delivered by PEI or PEI-StA complexes. The cells were then lysed, and
p-STAT3 levels were detected by Western blot as explained in details in the Materials and Methods section. Percentage of p-STAT3
silencing was calculated at each dose by comparing level of STAT3 of test group versus level of STAT3 in the untreated cells (considered
as 100%). The dose-response curve of p-STAT3 silencing percentage was plotted against anti-STAT3 siRNA concentration using a four-
parameter logistic function. (B) A representative Western blot analysis of B16 cells when treated with 50 nm of anti-STAT3 siRNA de-
livered by PEI or PEI-StA complexes. Identical complexes of NT siRNA as well as untreated B16 cells were used as controls. Bands’
optical intensities of p-STAT3 (black bars) and STAT3 (gray bars) were quantified and normalized to actin bands using the ImageJ soft-
ware. Data are shown as mean ± SD of four experiments. Statistical significance was determined compared with control (*P < .05) and
PEI-treated (aP < .05) groups. (C) Cell viability as well as apoptosis after 600 designated treatment were assessed by MTT assay (top)
and caspase 3 activity assay (bottom), respectively. Caspase 3 activity after the designated treatment was calculated as the difference in
the rates of substrate cleavage in the samples with and without specific caspase 3 inhibitor and expressed as nanomoles per minute per
104 cells. Data are shown as mean ± SD of seven to eight replicates for each sample. Statistical significance was determined compared
with control (*P < .05) and PEI-treated (aP < .05) groups.
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Figure 2. Restoration of DC phenotypic maturation in vitro. Primary DC cultures in day 7 were incubated with B16-CM of B16 culture that
was treated with anti-STAT3 siRNA or NT siRNA complexes of PEI or PEI-StA for 24 hours. (A, B) FCM analysis of CD86 and CD40
expression on the DC surface, respectively. In histograms (left), black lines indicate DCs exposed to B16-CM from siRNA-treated groups
(whether anti-STAT3 or s.c.), whereas gray shade indicates DCs exposed to untreated B16-CM control. Bar graphs (right) shows MFI
values after each treatment. Data are presented as a mean of three different measurements (±SD). (C) STAT3 knockdown in DCs re-
stores the capability of DCs to stimulate allogenic T-cell responses. Bars represent the level of T-cell proliferation (left) and IL-2 levels
detected in the culture supernatant (right). All data are shown as mean ± SD of at least triplicates for each sample. Statistical signifi-
cance was determined compared with control (*P < .05) and PEI-treated (aP < .05) groups.
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Alloreactivity of DCs from Tumor-Bearing Mice
To evaluate the functional maturation of DCs after STAT3 knock-
down in vivo, MLR between irradiated splenocytes from tumor-
bearing and allogenic T cells was conducted. As shown in (Figure 4C ,
top panel ), high allogenic T-cell proliferation was recorded after co-
culture with splenocytes from the STAT3 knockdown groups treated
with PEI and PEI-StA complexes. In addition, the measured cpm
was 1.5 times higher in the PEI-StA group than that in the PEI. This
was in agreement with our previous FCM results where PEI-StA in-
duced the highest expression of costimulatory molecules on DC surface
in vivo (data from Figure 4A). Consistently, IL-2 production con-
comitant to T-cell proliferation in PEI-StA group was around double
of that for the PEI group (Figure 4C , bottom panel ). These results in-
dicate more distal effects of local intratumoral silencing of STAT3
in B16 tumor by siRNA complexes particularly those of PEI-StA.
Tumor Infiltration of T Cells after STAT3 Knockdown
FCM analysis was conducted in tumor cell suspensions for CD3
expression, the signaling part of the T-cell receptor (TCR) complex.
As shown in Figure 5 (left panel ), STAT3 knockdown in B16 tumor
allowed for a profound CD3+ lymphocyte infiltration into tumor
mass reaching more than three- and fivefold increases with PEI
and PEI-StA groups compared with saline control, respectively. Dif-
ferential analysis of CD3+ population indicates an increase in CD4+
T helper cells, CD8+ cytotoxic T cells, and NKT cells (Figure 5, right
panel ). Moreover, because activated T cells produce IFN-γ, we mea-
sured the level of this cytokine in tumor cell supernatant. The ELISA
results detected a significant production of IFN-γ after STAT3 knock-
down, where PEI-StA allowed for ∼48% higher cytokine level than
PEI treatment (Figure 5, left panel ). This immunostimulatory profile
strongly suggests a role of the immune response in the antitumoral
effect recorded with siRNA-mediated STAT3 knockdown in B16 cells.
Discussion
Compelling evidence supporting the promise of interrupting STAT3
signaling pathway as a strategy for cancer therapy in solid and hema-
tological tumors (reviewed in Al Zaid Siddiquee and Turkson [22])
has accumulated. Recent studies on melanoma patients suggested
that tyrosine-phosphorylated STAT3 is a valid biomarker for atypical
nevi progression [23]. Moreover, activated STAT3 was found to have
permanent DNA-binding activity in primary human melanoma sam-
ples but not normal skin samples from the same patients [24]. Hence,
STAT3 was considered a potential target for chemoprevention and
treatment of melanoma. Furthermore, numerous studies showed that
targeting STAT3 in melanoma tumor models leads to the induction
of tumor regression [25], inhibition of angiogenesis [26], prevention
of metastasis [27], as well as activation of immune response [3,4].
Because constitutively activated STAT3 in tumors would negatively
influence multiple subsets of immune cells, it is logical to expect an
induction of the immune response after STAT3 disruption in tumors.
Figure 3. Tumor regression after STAT3 knockdown by anti-STAT3 siRNA complexes. B16 cells were inoculated subcutaneously (0.75 ×
106 cells per mice). NT or anti-STAT3 siRNA were administered daily by i.t. route from day 10 to day 13. At day 14, tumor dimensions
were obtained, and tumor volume was calculated accordingly for each subject. Isolated tumors from each group were then lysed for
Western blot analysis. (A) The value of tumor volume was plotted for each subject and presented as closed circles (top). Western blot
analysis (bottom) shows the expression level of p-STAT3, STAT3, and actin loading control. Bands’ optical intensities of p-STAT3 (black
bars) and STAT3 (gray bars) were quantified and normalized to actin bands using ImageJ software. Data are shown as mean ± SD of
four experiments. Statistical significance was determined compared with control (*P < .05) and PEI-treated (aP < .05) groups. (B) Pic-
tures of three representative mice per treatment group at the end point of the study (24 hours after last dose).
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In fact, such effect is not thought to be totally associated with direct
STAT3 disruption in immune cells because they were not intended
for manipulation but rather a consequence for the anti-STAT3 effect
in tumor cells, that is, a bystander effect.
Bystander effects as a result of STAT3 inhibition were first described
in B16 murine melanoma transfected with dominant-negative form
of STAT3 [28]. In that study, unpredicted cytotoxicity was noted
in neighboring tumor cells that never received the dominant-negative
Figure 4. Activation of tumor-infiltrating DCs in vivo. At the end point of siRNA treatment (as described in Figure 3), tumor samples were
isolated and crushed between two slides into uniform cell suspensions. Cellular component as well as supernatant of each group was
analyzed by FCM and ELISA, respectively. (A) Bar graph (top) represents the fold increase of CD11c+ cells in the tumor cell suspensions
of different treatment groups (compared with saline-treated group). Data are shown as mean ± SD of three measurements. Statistical
significance was determined compared with control (*P < .05). Histograms (bottom) show the expression pattern of DC activation
markers CD86 and CD40 in the tumor cell suspensions obtained from different treatment groups. The percentage of cells of the gated
population is indicated in the upper right corner of each histogram, whereas the populations of cells in-gate and out-of-gate were sep-
arated by the vertical line in each histogram. (B) Cytokine levels measured in tumor sample supernatants by ELISA were plotted in bar
graphs for IL-12 (top) and TNF-α (bottom). Data are shown as mean ± SD of three measurements. Statistical significance was deter-
mined compared with control (*P < .05) and PEI-treated (aP < .05) groups. (C) Allogenic MLR after STAT3 silencing in vivo. Splenocytes
from tumor-bearing mice were collected, irradiated, and cocultured with allogenic T cells. Bars represent the level of T-cell proliferation
(top), and IL-2 levels were detected in the supernatant (bottom). All data are shown as mean ± SD of five replicates for each sample.
Statistical significance was determined compared with control (*P < .05) and PEI (aP < .05).
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treatment. Subsequent studies in this focus have isolated three pos-
sible mechanisms after STAT3 inhibition by which bystander effects
could be mediated: (i) production of soluble factors that induce tumor
apoptosis [29], (ii) suppressed angiogenesis as determined by VEGF
down-regulation [26], and (iii) involvement of innate and adaptive
antitumor immune response as indicated by the production of pro-
inflammatory mediators and infiltration of macrophages, neutrophils,
and T cells in the tumor mass [3,10]. The last that gained special focus
of the scientific community as a widely progressing area of research
today comprises chemotherapy and immunotherapy for cancer [30].
We have recently showed that siRNA-mediated STAT3 silencing
in B16.F10 via intratumoral administration of siRNA/PEI complexes
results in a remarkable tumor regression [18]. Along with direct tu-
mor apoptosis, molecular investigation in that study revealed two
possible bystander effects: increase in IL-6 and decrease in VEGF lev-
els in tumor microenvironment [18]. We hypothesized that the anti-
tumor activity observed subsequent to STAT3 knockdown is partly
owed to the breakdown of immunosuppressive microenvironment
leading to improvements in DC maturation, immune cell activation,
and trafficking to the tumor. The validity of this hypothesis was
investigated in the current study through assessing the bystander
immune response after STAT3 knockdown in B16 melanoma cells
in vitro and in vivo using siRNA complexes of PEI and its stearic acid
derivative. In our approach to evaluate the immunologic picture after
siRNA intervention, we focused on three aspects: the level of im-
mune cell maturation and activation, percentage of tumor-infiltrating
lymphocytes, and cytokine profiles in tumor milieu.
DCs are professional antigen-presenting cells that form a crucial
link between innate and adaptive immune system. In normal situa-
tions, DCs recognize antigens from normal, microbial, or tumoral
origins [31]. These antigens get processed and presented in the con-
text of major histocompatibility complex class I and II to be recog-
nized by CD8+ and CD4+ T cells, respectively [32]. Nevertheless,
DCs must provide three signals to activate naive T cells: antigen pre-
sentation in the context of major histocompatibility complex class I
and II (signal 1), costimulation provided by molecules such as CD86 and
CD40 that interact with their ligands on T-cell surface (signal 2), and
cytokine stimulation (signal 3) to polarize T cells toward intended re-
sponse, for example, antitumoral response. However, tumors secrete
factors that inhibit DC differentiation and maturation and eventually
Figure 5. Activation of tumor-infiltrating lymphocytes in vivo. Tumor samples from different treatment groups were isolated (as de-
scribed in Figure 4) and analyzed for the presence and activation of tumor-infiltrating lymphocytes. Bar graphs (left) represent percent-
ages of cells positive for CD3 (T-cell marker) (top) and the amount of IFN-γ detected in the tumor supernatants from different treatment
groups (bottom). Data are shown as mean ± SD of three measurements. Statistical significance was determined compared with control
(*P < .05) and PEI (aP < .05). Histograms (right) show the differential lymphocyte population markers CD4, CD8, and NK1.1 for the
designated treatment groups. Percentage of cells of the gated population is indicated in the upper right corner of each histogram,
whereas the populations of cells in-gate and out-of-gate were separated by the vertical line in each histogram.
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evade the adaptive immune response through this strategy [4]. In fact,
DC malfunction due to TDFs is documented in melanoma patients
[4]. To mimic this situation, we conducted an in vitro study where
DCs were exposed to B16-CMwith or without siRNA treatment (Fig-
ures 1 and 2). Our in vitro study indicates that (i) phenotypical and
functional maturation of DCs can be restored after cancer cell manip-
ulation with STAT3 siRNA complexes and that (ii) the level of DC
activation is correlated with the level of STAT3 knockdown in B16
cells. We show that DC alloreactivity (Figure 2C ) was noticed only
with groups that showed a higher expression of the costimulatory mol-
ecules CD86 and CD40 (Figure 2A and B). This is an important
observation because it proves that B16-CM–treated DCs became
functional after siRNA manipulation of B16 cells. The CD86 and
CD40molecules onDC surface interact with CD28 and CD40 ligand
(CD40L) on T-cell surface. Such interaction is beneficial for both DCs
and T cells where stimulation of CD28 stabilizes CD40L on T cells
and stimulation of CD40 on DCs increases their expression of CD86
molecules [33,34]. Therefore, functional and phenotypic maturation
of DCs are both required for naive T-cell activation. Moreover, we
noticed that STAT3 knockdown of B16 cells with PEI-StA complexes
of siRNA leads to higher phenotypic and functional maturation of
DCs. This is consistent with our previous results where PEI-StA com-
plexes were more potent in STAT3 knockdown and caused higher
cell killing effect on B16 cells [18]. One reason for the superior effect
of PEI-StA complexes reflected on DC 415 activation is the exponen-
tial nature of B16 cell death. It has been suggested that B16 apoptosis
after STAT3 disruption involves the production of soluble factors
such as TNF-related apoptosis-inducing ligand, which induces tumor
cell death [29,35]. Such effect has shown to improve antitumoral func-
tion of DCs in vitro and in vivo [36]. Nevertheless, detailed analysis of
B16-CM is still needed to pinpoint factors responsible for DC activa-
tion. These proof-of-concept results demonstrate that manipulation of
STAT3 in tumor cell culture has a positive effect on DC activation.
A similar effect was noticed after STAT3 knockdown in vivo. The
recorded B16 tumor regression (Figure 3) was associated with DC
activation (Figure 4) and lymphocytes infiltration (Figure 5). Consis-
tent with our previous findings, STAT3 silencing by siRNA/PEI-StA
complexes was superior to that of PEI owing to the higher protective
effect of PEI-StA toward siRNA [18]. Consequently, we observed a
significant infiltration of CD11c+ DCs in tumor tissue (Figure 4A,
top panel ). However, we also noted a comparable DC infiltration for
groups treated with PEI and PEI-StA complexes. Such picture is
quite logical in vivo because DCs traffic out of the site of antigen
encounter to the spleen and draining lymph node to present the
antigen to naive T cells [37]. Considering the fact that DC influx
and efflux in and out of tumor mass is a continuous process, whereas
the FCM analysis was performed in a specific time point, the differ-
ence in DC infiltration between the two formulations is irrelevant. In
this case, a more important factor is the level of DC activation. Here
we noticed an advantage for PEI-StA over PEI in CD86 and CD40
expression (Figure 4A, bottom panel) as well as levels of proinflamma-
tory cytokines IL-12 and TNF-α (Figure 4B). DCs are known to
produce IL-12 and TNF-α on capturing tumor antigen [38]. The
production of IL-12 was recently found to be an absolute require-
ment for TH1-type immune response that leads to CTL antitumor
response [39]. TNF-α was also shown to enhance DC maturation
and promote antitumor immune response [40]. The DC activation
results were corroborated with our MLR study. Here we show that
on STAT3 knockdown in vivo, DCs in the spleens of tumor-bearing
mice showed more alloreactivity with allogenic T cells (Figure 4C ).
The noted advantage of PEI-StA group supports our argument that
activated DCs are home to secondary lymphoid organs because more
indicative results are demonstrated in those organs. Moreover, we
find the results of clinical significance because some evidence showed
that peripheral blood DCs induce lower allogenic MLR in a study
done on 32 breast cancer patients [41]. Hence, a high MLR outcome
can be considered a positive indicator of the therapeutic approach.
Furthermore, a high level of TIL was recorded after tumor regres-
sion after STAT3 knockdown was proved by the high level of CD3+
cells (Figure 5, left panel ). In that population, the superiority of PEI-
StA treatment was noted by the induced infiltration of CD4+ T cells,
CD8+ T cells, and NKT cells (Figure 5, right panel ). This high pres-
ence of TIL indicates three incidents in this study: stimulation of an
innate immune response after tumor regression, imminent DC acti-
vation after siRNA intervention because T-cell immune response is a
latent response, and, finally, the noted tumor regression is also me-
diated by CTL response. The latter is explained by the approximately
fourfold reduction in tumor volume after PEI-StA administration
compared with PEI. Moreover, IFN-γ was positively correlated with
TIL level (Figure 5, left panel ). This proinflammatory cytokines is
produced by activated CD4+ T cells, CD8+ CTL, NK cells, and
NKT cells and plays a crucial role in antitumor immunity [42]. In
fact, IFN-γ production is directly related to suppression of B16 cell
growth [43]. Moreover, the results of in vivo DC activation (data
from Figure 4) highly correlate with these results because the pro-
duction of IL-12 by DCs and other phagocytes is known to induce
IFN-γ production [39]. TNF-α was demonstrated to induce T-cell
activation as well [40]. However, it is also important to know that
our siRNA complexes may not have an exclusive effect on cancer
cells. In vivo, the siRNA complexes might have directly affected im-
mune cells as well as cancer cells. This is a therapeutically relevant ap-
proach because blocking STAT3 in tumor as well as immune cells can
produce a synergistic antitumor effect [10]. Such effect was evidenced
by the elegant work of Hua Yu’s group where the authors demon-
strated the requirement of immune cells for tumor regression using
tumor-bearing mouse model with STAT3−/− hematopoietic system
[6]. Taken together, the collective picture of our work proves that
manipulation of tumoral STAT3 is crucial for the generation of ro-
bust innate and adaptive immune responses.
Conclusions
We developed polymeric nontoxic formulations of siRNA for specific
STAT3 knockdown in B16 tumor. The siRNA-mediated silencing of
STAT3 in B16 melanoma cells was found to be able to break the
state of immune tolerance used by the tumor and induce bystander
antitumor innate and adaptive immune response. We also found that
the bystander effect is highly correlated to the siRNA silencing effect
and the tumor-killing action. Such strategy. This strategy could be
beneficial as an adjuvant therapy along with chemotherapy and/or
immunotherapy for cancer.
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